|
US5686465A
(en)
|
1988-10-31 |
1997-11-11 |
Endorecherche Inc. |
Sex steroid activity inhibitors
|
|
US5395842A
(en)
|
1988-10-31 |
1995-03-07 |
Endorecherche Inc. |
Anti-estrogenic compounds and compositions
|
|
US5254568A
(en)
|
1990-08-09 |
1993-10-19 |
Council Of Scientific & Industrial Research |
Benzopyrans as antiestrogenic agents
|
|
DE69023906T2
(de)
|
1990-08-09 |
1996-04-11 |
Council Scient Ind Res |
Benzopyrane und Verfahren zu deren Herstellung.
|
|
US6060503A
(en)
*
|
1991-12-02 |
2000-05-09 |
Endorecherche, Inc. |
Benzopyran-containing compounds and method for their use
|
|
CZ285522B6
(cs)
|
1993-06-24 |
1999-08-11 |
Eli Lilly And Company |
Farmaceutický prostředek pro snížení koncentrace glukosy v krvi
|
|
US5446061A
(en)
|
1993-11-05 |
1995-08-29 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
US5407947A
(en)
*
|
1993-11-05 |
1995-04-18 |
Eli Lilly And Company |
Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
|
|
US5416098A
(en)
|
1993-12-30 |
1995-05-16 |
Zymogenetics, Inc. |
Method for treating dermatitis and related conditions
|
|
US5389646A
(en)
|
1993-12-30 |
1995-02-14 |
Zymogenetics, Inc. |
Methods for treatment and prevention of bone loss using 2,3-benzopyrans
|
|
US5681835A
(en)
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
|
UA41909C2
(uk)
|
1994-07-22 |
2001-10-15 |
Елі Ліллі Енд Компані |
Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
|
|
US5637598A
(en)
|
1994-11-18 |
1997-06-10 |
Eli Lilly And Company |
Methods of inhibiting bone loss
|
|
US5446071A
(en)
|
1994-11-18 |
1995-08-29 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
US5980938A
(en)
|
1996-07-15 |
1999-11-09 |
Eli Lilly And Company |
Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
|
|
ES2188908T3
(es)
*
|
1996-10-28 |
2003-07-01 |
Novo Nordisk As |
Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos.
|
|
AU8102398A
(en)
|
1997-07-09 |
1999-02-08 |
Central Drug Research Institute |
(dl)-2,3-diaryl-2h-1-benzopyrans
|
|
AU8102498A
(en)
|
1997-07-09 |
1999-02-08 |
Central Drug Research Institute |
Preparation of diaryl-benzopyrans
|
|
CZ300929B6
(cs)
|
1997-08-15 |
2009-09-16 |
Duke University |
Sloucenina pro použití pri lécení nebo prevenci estrogenem stimulované rakoviny
|
|
ID24568A
(id)
|
1997-11-06 |
2000-07-27 |
American Home Prod |
Kontrasepsi oral yang mengandung anti-estrogen plus progestin
|
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
|
CA2324060A1
(en)
|
1998-03-30 |
1999-10-07 |
The Regents Of The University Of California |
Methods and compounds for modulating nuclear receptor activity
|
|
EP1068529A4
(en)
|
1998-03-30 |
2004-08-04 |
Univ California |
METHODS AND CONNECTIONS FOR MODULATING THE CORE RECEPTOR-COACTIVATOR BINDING
|
|
US6465445B1
(en)
|
1998-06-11 |
2002-10-15 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
US7005428B1
(en)
|
1998-06-11 |
2006-02-28 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
WO2000009493A1
(en)
|
1998-08-14 |
2000-02-24 |
Schering Corporation |
Enantioselective synthesis
|
|
US6262270B1
(en)
*
|
1998-08-14 |
2001-07-17 |
Schering Corporation |
Enantioselective synthesis
|
|
AU2156800A
(en)
|
1998-12-18 |
2000-07-12 |
Schering Corporation |
Oral antiestrogen pharmaceutical composition
|
|
US6638727B1
(en)
|
1999-01-26 |
2003-10-28 |
Cytyc Health Corporation |
Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
|
|
US6716452B1
(en)
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
DE19916419B4
(de)
|
1999-04-08 |
2005-06-16 |
Schering Ag |
Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
|
|
AU5957500A
(en)
|
1999-07-06 |
2001-01-22 |
Endorecherche Inc. |
Methods of treating and/or suppressing weight gain
|
|
WO2001026651A2
(en)
|
1999-10-14 |
2001-04-19 |
Endorecherche, Inc. |
Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
|
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
|
SK9592002A3
(en)
|
2000-01-28 |
2003-12-02 |
Endorech Inc |
A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit
|
|
AU2001238700A1
(en)
|
2000-02-22 |
2001-09-03 |
Board Of Regents, The University Of Texas System |
Compositions and methods of use of het, a novel modulator of estrogen action
|
|
DE10013782A1
(de)
*
|
2000-03-15 |
2001-10-18 |
Schering Ag |
4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
US6528681B2
(en)
|
2000-04-05 |
2003-03-04 |
Bristol-Meyers Squibb Pharma Company |
Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
|
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
US7863011B2
(en)
|
2000-05-10 |
2011-01-04 |
Signe Biopharma, Inc. |
Screening method for predicting susceptibility to breast cancer
|
|
US8119138B2
(en)
|
2000-05-10 |
2012-02-21 |
Signe Biopharma Inc. |
Anti-estrogen and immune modulator combinations for treating breast cancer
|
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
|
DK1318837T3
(da)
|
2000-08-11 |
2005-01-10 |
Wyeth Corp |
Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
|
|
US20020099013A1
(en)
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
|
CN1729002A
(zh)
|
2000-09-08 |
2006-02-01 |
法玛西雅意大利公司 |
依西美坦作为化学预防剂
|
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
|
HUP0301276A2
(hu)
|
2000-10-06 |
2003-11-28 |
Biomedicines, Inc. |
Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
|
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
|
|
WO2002032373A2
(en)
|
2000-10-19 |
2002-04-25 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
SK4772003A3
(en)
|
2000-10-19 |
2003-08-05 |
Merck & Co Inc |
Estrogen receptor modulators
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
MXPA03006607A
(es)
|
2001-01-26 |
2003-09-22 |
Upjohn Co |
Metodo combinado para tratar trastornos dependientes de hormonas.
|
|
US20040082557A1
(en)
|
2001-01-26 |
2004-04-29 |
Wajszczuk Charles Paul |
Methods for treating estrogen-dependent disorders
|
|
GB2374412A
(en)
|
2001-04-11 |
2002-10-16 |
Karobio Ab |
Hypertension treatment and assay
|
|
AU2002323098A1
(en)
|
2001-08-11 |
2003-03-03 |
Bristol-Myers Squibb Pharma Company |
Selective estrogen receptor modulators
|
|
WO2003026568A2
(en)
|
2001-09-21 |
2003-04-03 |
Merck & Co., Inc. |
Androstanes as androgen receptor modulators
|
|
EP1434786A4
(en)
|
2001-10-03 |
2009-03-25 |
Merck & Co Inc |
ANDROSTAN-17-BETA-CARBOXAMIDE AS MODULATORS OF THE ANDROGEN RECEPTOR
|
|
NZ532064A
(en)
|
2001-10-10 |
2006-04-28 |
Pharmacia Italia Spa |
Methods for preventing and treating bone loss with steroid compounds
|
|
WO2003034987A2
(en)
|
2001-10-19 |
2003-05-01 |
Merck & Co., Inc. |
Androgen receptor modulators and methods of use thereof
|
|
MXPA04006034A
(es)
*
|
2001-12-19 |
2005-03-31 |
Johnson & Johnson |
Heterocompuestos tetraciclicos como moduladores de receptor de estroeno.
|
|
US7105679B2
(en)
*
|
2001-12-19 |
2006-09-12 |
Kanojia Ramesh M |
Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
|
|
JP2005524630A
(ja)
|
2002-01-14 |
2005-08-18 |
ノルディック・ビオサイエンス・エー／エス |
エストロゲン受容体を介する軟骨破壊の抑制
|
|
AU2003206442A1
(en)
|
2002-02-21 |
2003-09-09 |
Pantarhei Bioscience B.V. |
Estrogenic component for treating decreased libido in women
|
|
IL163825A0
(en)
|
2002-03-13 |
2005-12-18 |
Merck & Co Inc |
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
|
|
WO2003076660A1
(en)
|
2002-03-13 |
2003-09-18 |
F.Hoffmann-La Roche Ag |
Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
|
|
US20030225132A1
(en)
|
2002-04-11 |
2003-12-04 |
Dininno Frank P. |
Estrogen receptor modulators
|
|
JP4554219B2
(ja)
|
2002-04-24 |
2010-09-29 |
メルク・シャープ・エンド・ドーム・コーポレイション |
エストロゲン受容体調節剤
|
|
JP4516839B2
(ja)
|
2002-04-30 |
2010-08-04 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アンドロゲン受容体修飾因子としての４−アザステロイド誘導体
|
|
BR0312024A
(pt)
|
2002-06-25 |
2005-03-22 |
Wyeth Corp |
Uso de derivados de ciclotiocarbamato no tratamento de condições relacionadas com hormÈnios
|
|
IL165395A0
(en)
|
2002-06-25 |
2006-01-15 |
Wyeth Corp |
Use of thio-oxubdile derivatives in treatment of hormone-related conditions
|
|
AU2003286757B2
(en)
|
2002-11-01 |
2009-06-04 |
Merck Sharp & Dohme Corp. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
|
WO2004091488A2
(en)
|
2003-04-14 |
2004-10-28 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
JP4832303B2
(ja)
|
2003-05-07 |
2011-12-07 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アンドロゲン受容体モジュレータおよびこれらの使用
|
|
DK1622630T3
(da)
|
2003-05-07 |
2012-12-17 |
Osteologix As |
P009368epdk1
|
|
US20040248989A1
(en)
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
|
AU2004255200A1
(en)
|
2003-06-30 |
2005-01-20 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
JP2007521292A
(ja)
|
2003-06-30 |
2007-08-02 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレータとしての１７−アセトアミド−４−アザステロイド誘導体
|
|
AU2004259664B2
(en)
|
2003-06-30 |
2009-05-28 |
Merck Sharp & Dohme Corp. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
AU2004256075B2
(en)
|
2003-06-30 |
2008-12-04 |
Merck Sharp & Dohme Corp. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
CA2537663A1
(en)
|
2003-09-10 |
2005-03-24 |
Merck & Co., Inc. |
17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
|
|
JP2007505120A
(ja)
|
2003-09-10 |
2007-03-08 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体調節因子としての１７−複素環式−４−アザステロイド誘導体。
|
|
ATE399775T1
(de)
|
2003-10-08 |
2008-07-15 |
Smithkline Beecham Corp |
Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
|
|
AU2004288196B2
(en)
|
2003-10-31 |
2009-11-26 |
Merck Sharp & Dohme Corp. |
21-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
|
|
WO2005073190A1
(en)
|
2004-01-29 |
2005-08-11 |
Eli Lilly And Company |
Selective estrogen receptor modulators
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
WO2005123130A2
(en)
|
2004-06-17 |
2005-12-29 |
Osteologix A/S |
Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
|
|
JP2008502609A
(ja)
|
2004-06-17 |
2008-01-31 |
オステオロジックス エイ／エス |
リウマチおよび関節性疾患の治療改善方法
|
|
JP2008511615A
(ja)
|
2004-09-03 |
2008-04-17 |
ホルモス メディカル リミテッド |
アンドロゲン欠乏症の治療法または予防法に使用する医薬調製物の製造に用いるエストロゲン受容体選択的調節物質
|
|
CN106138065A
(zh)
|
2004-10-20 |
2016-11-23 |
恩多研究公司 |
性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
|
|
WO2006084937A1
(en)
|
2005-02-14 |
2006-08-17 |
Leskelae Hannu-Ville |
Method for diagnosing and treating women with increased response to hormonal replacement therapy
|
|
US20070078114A1
(en)
|
2005-09-02 |
2007-04-05 |
Myriad Genetics, Incorporated |
Combination therapy for alzheimer's disease and other diseases
|
|
WO2007098090A2
(en)
|
2006-02-17 |
2007-08-30 |
Novacea, Inc. |
Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators
|
|
US20080268041A1
(en)
|
2007-04-23 |
2008-10-30 |
Jens Hoffmann |
Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
|
|
DE102007026877A1
(de)
|
2007-06-08 |
2008-12-11 |
Bayer Schering Pharma Aktiengesellschaft |
Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
|
|
US20110104121A1
(en)
|
2008-05-21 |
2011-05-05 |
Wira Charles R |
Female Reproductive Tract and Anal Prophylaxes
|
|
WO2010107474A1
(en)
|
2009-03-16 |
2010-09-23 |
The Research Foundation Of State University Of New York |
Antiestrogens for breast cancer therapy
|
|
US20100317635A1
(en)
|
2009-06-16 |
2010-12-16 |
Endorecherche, Inc. |
Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
|
|
BR112012031464A2
(pt)
|
2010-06-10 |
2020-08-04 |
Aragon Pharmaceuticals, Inc. |
moduladores do receptor de estrogênio e os seus usos
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
AU2011347718B2
(en)
|
2010-12-24 |
2016-06-23 |
Msd Oss B.V. |
N-substituted azetidine derivatives
|
|
SG11201403002RA
(en)
|
2011-12-14 |
2014-07-30 |
Seragon Pharmaceuticals Inc |
Fluorinated estrogen receptor modulators and uses thereof
|
|
EA201490897A1
(ru)
|
2011-12-16 |
2015-03-31 |
Олема Фармасьютикалс, Инк. |
Новые бензопирановые соединения, композиции и их применение
|